Baldwin Insurance Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $BWIN in the last 7 days.
No SEC Form 4 filings for $BWIN in the last 30 days.
See all $BWIN insider activity →TD Cowen downgraded Baldwin Insurance to Hold, setting a $32.50 price target, implying a 2.0% upside from the Oct 9 close. The firm cited economic pressures on revenue growth and concerns over underwriting performance in its MGA segment.
Ryan Specialty (private) beat estimates but stock fell 14.5% to $37.69. Brown & Brown (BRO) reported $1.68B revenue, up 30.4% YoY, missing estimates, stock down 14% to $59.95. Baldwin Insurance (BWIN) reported $492.9M revenue, up 30.1% YoY, in line with estimates, stock up 19% to $31.77. Marsh (MRSH) reported $7.40B revenue, up 6.2% YoY, beating estimates, stock down 6.6% to $170.06.
Baldwin Insurance (BWIN) was downgraded by UBS from Buy to Neutral, with a price target lowered from $37.00 to $32.50. The company's stock is currently overvalued by 7.6% according to GF Value™. BWIN has a GF Score™ of 77/100, indicating solid performance but concerns over financial strength.
Recent BWIN coverage spans earnings, market movers and financial news.
Downgrade and lower conviction on underwriting sustainability likely pressure the stock versus prior rating, with downside risk tied to P&C pricing and MGA profitability.
Positive price move may stabilize but no new catalyst beyond the reported numbers.
The downgrade signals weaker outlook and may trigger selling pressure.
The downgrade and lower price target suggest near‑term downside pressure despite the premium offered in the buyout.
The stock is expected to trade near the cash offer with limited upside.
AlphAI scores every news story that mentions BWIN with an AI model for sentiment and relevance, and aggregates insider trades from Baldwin Insurance Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TD Cowen downgraded Baldwin Insurance to Hold, setting a $32.50 price target, implying a 2.0% upside from the Oct 9 close. The firm cited economic pressures on revenue growth and concerns over underwriting performance in its MGA segment.
2 min readRyan Specialty (private) beat estimates but stock fell 14.5% to $37.69. Brown & Brown (BRO) reported $1.68B revenue, up 30.4% YoY, missing estimates, stock down 14% to $59.95. Baldwin Insurance (BWIN) reported $492.9M revenue, up 30.1% YoY, in line with estimates, stock up 19% to $31.77. Marsh (MRSH) reported $7.40B revenue, up 6.2% YoY, beating estimates, stock down 6.6% to $170.06.
2 min readBaldwin Insurance (BWIN) was downgraded by UBS from Buy to Neutral, with a price target lowered from $37.00 to $32.50. The company's stock is currently overvalued by 7.6% according to GF Value™. BWIN has a GF Score™ of 77/100, indicating solid performance but concerns over financial strength.
2 min readUBS downgraded Baldwin Insurance (NASDAQ:BWIN) to Neutral, lowering its price target to $32.50. The company agreed to a $32.50 per share take-private deal led by Sequence Holdings and Michael Dell’s family office, implying an enterprise value of $7.7B. The stock has surged 42% over six months. Baldwin's Q2 2026 EPS beat estimates, but revenue missed, and it lowered its full-year growth outlook.
2 min readThe Baldwin Insurance Group (BWIN) agreed to a $7.7 billion buyout by DFO Management and Sequence Holdings, offering shareholders $32.50 per share, an 88% premium. Baldwin's Q2 revenue grew 30% to $492.9 million, with adjusted EBITDA up 37%. The deal, pending approvals, is expected to close in Q1 2027, providing immediate value but limiting future upside for public investors.
2 min readStifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.
2 min readBaldwin Insurance Group, Inc. (BWIN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on June 4, 2026, the Board of Directors of The Baldwin Insurance Group, Inc. (the “Company”) appoi
1 min readMichael Dell is acquiring Baldwin & Co. (BWIN) for $7.7B. Baldwin reported Q2 revenue of $492.9M (+30% YoY), adjusted net income of $68.5M, and adjusted EBITDA of $116.7M (+37%). Management guided Q3 revenue to $485M-$495M and full-year revenue to $2.01B-$2.05B. Analysts have mixed targets, with a consensus 'Moderate Buy' and average target of $33.
2 min readRyan Specialty beat estimates but fell 11.1% to $39.20. Brown & Brown (BRO) reported $1.68B revenue, up 30.4% YoY, missing estimates by 2.5%, and dropped 3.4% to $67.32. Arthur J. Gallagher (AJG) reported $4.00B revenue, up 24.3% YoY, missing estimates by 0.5%, and fell 3.3% to $248.05. Marsh (MRSH) reported $7.40B revenue, up 6.2% YoY, beating estimates by 1.8%, and dropped 1.2% to $179.91.
2 min readCorning (GLW) fell 12.7% after announcing a $2B stock sale plan. Baldwin Insurance (BWIN) rose 7.9% on a $7.7B private equity deal. Gartner (IT) gained 7.7% at its tech conference. Jabil (JBL) dropped 5.1% on a lowered price target. Accenture (ACN) rose 5.2% after a price target increase.
2 min read
